Skip to content
Research Article Open access CC BY 4.0

Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia

A. D’Alessio, M. Cottini, C. Lombardi, M. Uccelli, F. Bracchi, G. Cesana, D. Di Mauro, A. Fargnoli, C. Giussani, F. Martini, M. Motta, S. Olmi, N. Sertori, M. Taverna, P. Del Poggio

Asian Journal of Medicine and Health · pp. 15–26 · Published 20 Mar 2021

10.9734/ajmah/2021/v19i230301

Abstract

Background: Hydroxychloroquine (HCQ) has been used against SARS-CoV-2, but large non randomized studies failed to show any clinical benefit. However, in these studies the drug was started in the hospital setting, a significant time after the onset of symptoms. Aim of the Study: to verify if HCQ, given early after the onset of symptoms and in the outpatient setting, can reduce hospital admissions and improve clinical outcomes of COVID-19 Methods: We performed a retrospective study on 824 patients with COVID-19 pneumonia in the Bergamo province (Lombardy, Italy). Patients were divided in 2 cohorts: the first included 354 outpatients attended by Primary Care Physicians (PCP), the second included 470 patients admitted to an Emergency Department (ED) during the same period. We compared rate of hospital admission and clinical outcomes in patients treated with HCQ within 6 days from the onset of symptoms, with all other patients. Clinical outcomes were evaluated at a 1-month time-point. Results: Patients who received early treatment with HCQ showed a lower rate of hospital admissions (p<0.0001), mechanical ventilation (p<0.0022) and need for oxygen supplementation at home (p=0.002) in the first cohort and improved survival in the second (p=0.03). Early treatment with HCQ was the only independent variable influencing all predefined outcomes on multivariate analysis. Conclusions: Treatment with HCQ, initiated within 6 days from the onset of COVID-19 may improve both clinical outcome and rate of hospital admissions.

SARS-CoV-2 COVID-19 hydroxychloroquine

References (29)

  1. 1 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
  2. 2 Remdesivir for the Treatment of Covid-19 — Final Report [DOI]
  3. 3 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
  4. 4 Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases [DOI]
  5. 5 RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
  6. 6 Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy [DOI]
  7. 7 Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study [DOI]
  8. 8 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [DOI]
  9. 9 Compassionate Use of Remdesivir for Patients with Severe Covid-19 [DOI]
  10. 10 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [DOI]
  11. 11 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
  12. 12 Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) [DOI]
  13. 13 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [DOI]
  14. 14 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 [DOI]
  15. 15 Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial [DOI]
  16. 16 Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State [DOI]
  17. 17 Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study [DOI]
  18. 18 Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 [DOI]
  19. 19 Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data [DOI]
  20. 20 Annals of Internal Medicine Drug-Associated Infective Endocarditis Trends : What ' s All the Buzz About ? [DOI]
  21. 21 Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis [DOI]
  22. 22 Risk Factors for Mortality in Patients with COVID-19 in New York City [DOI]
  23. 23 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection [DOI]
  24. 24 Adaptations and Lessons in the Province of Bergamo [DOI]
  25. 25 COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology [DOI]
  26. 26 Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world [DOI]
  27. 27 Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection [DOI]
  28. 28 Guidance for communicating research findings to participants [DOI]
  29. 29 Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

83

Page views

0

PDF downloads

37

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.